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ABSTRACT
Therapy-related myeloid neoplasms (t-MN) may occur as a late effect of cytotoxic 
therapy for a primary malignancy or autoimmune diseases in susceptible individuals. 
We studied the development of somatic mutations in t-MN, using a collection of follow-
up samples from 14 patients with a primary hematologic malignancy, who developed 
a secondary leukemia (13 t-MN and 1 t-acute lymphoblastic leukemia), at a median 
latency of 73 months (range 18-108) from primary cancer diagnosis.
Using Sanger and next generation sequencing (NGS) approaches we identified 
8 mutations (IDH1 R132H, ASXL1 Y591*, ASXL1 S689*, ASXL1 R693*, SRSF2 P95H, 
SF3B1 K700E, SETBP1 G870R and TP53 Y220C) in seven of thirteen t-MN patients 
(54%), whereas the t-ALL patient had a t(4,11) translocation, resulting in the KMT2A/
AFF1 fusion gene. These mutations were then tracked backwards in marrow samples 
preceding secondary leukemia occurrence, using pyrosequencing and a NGS protocol 
that allows the detection of low variant allele frequencies (≥0.1%).
Somatic mutations were detectable in the BM harvested at the primary diagnosis, 
prior to any cytotoxic treatment in three patients, while they were not detectable and 
apparently acquired by the t-MN clone in five patients.
These data show that clonal evolution in t-MN is heterogeneous, with some 
somatic mutations preceding cytotoxic treatment and possibly favoring leukemic 
development.
INTRODUCTION
Therapy-related myeloid neoplasms include 
myelodysplastic syndromes (MDS) and acute myeloid 
leukemia (AML) occurring as a late effect of chemo- 
and/or radiotherapy for a primary malignancy or an 
autoimmune disease and have been included in the WHO 
classification of acute leukemia [1–3]. Although the 
majority of t-MN are of myeloid lineage, therapy-related 
acute lymphoblastic leukemia (t-ALL) has been also 
reported [4–5].
t-MN are characterized by high incidence 
of complex karyotypes, frequent abnormalities of 
chromosome 7 and/or 5 (monosomies and/or deletions) 
and TP53 mutations in 10-30% of patients [1, 6–8]. On 
the other hand, somatic mutations recently identified 
in patients with de novo AML and MDS, such as those 
of epigenetic regulators, spliceosome machinery and 
SETBP1, are rare, with the exception of SRSF2 [9–
11]. t-ALL are frequently associated with exposure to 
alkylating agents and/or topoisomerase II inhibitors [5–
12]. Balanced translocations involving the gene KMT2A 
at 11q23, with a high prevalence of the t(4;11)(q21;q23) 
translocation have been commonly reported [5–12].
Cytotoxic therapy may induce chromosomal 
alterations and genetic mutations in hematopoietic 
progenitors, leading to a high incidence of complex 
karyotypes. TP53 mutations in the founding clone are 
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major contributors to genetic instability and have also been 
associated to the occurrence of cytogenetic abnormalities 
and poor response to chemotherapy that are typical of 
t-MN. A different scenario has been recently depicted by 
Wong et al, who showed that the number of somatic single 
nucleotide variants (SNV) in t-MN was similar to that of 
de novo AML and MDS, suggesting that cytotoxic therapy 
does not induce genome-wide DNA damage [13]. On the 
other hand, using a modified next generation sequencing 
(NGS) protocol that allows the detection of very low TP53 
variant allele frequencies, the authors of this study found 
the same TP53 mutation identified at the time of t-MN 
diagnosis in bone marrow (BM) samples collected prior 
to any chemotherapy. In this line, somatic mutations in 
genes associated to hematological malignancies have been 
found in the peripheral blood of elderly otherwise healthy 
individuals, suggesting that mutations can naturally occur 
in hematopoietic cells [14–15].
The incidence of t-MN has been increasing in the 
past years [16]. Although this increase can be attributed 
to the numerical expansion and the prolonged survival 
of treated patients, the identification of mechanisms 
explaining the underlying individual susceptibility to 
t-MN development could be useful to limit the risk of this 
complication.
The aim of our study was to investigate the role of 
common somatic mutations and other gene alterations 
during clonal evolution of 14 therapy-related leukemia 
patients (13 t-MN and 1 t- ALL) for whom we had 
collected BM samples at the time of primary diagnosis of 
a hematological neoplasm and/or during its follow-up. At 
the time of t-MN diagnosis, we studied mutations in genes 
belonging to epigenetic regulators (DNMT3A, IDH1, 
IDH2 and ASXL1), spliceosome enzymes (U2AF1, SF3B1 
and SRSF2), TP53, SETBP1, NRAS and KRAS. Mutations 
identified in the t-MN were then tracked backwards in 
previous samples using high sensitivity techniques, as 
NGS or pyrosequencing.
RESULTS
Screening of genetic changes in therapy-related 
neoplasms
Our first aim was the genetic characterization of 13 
t-MN and one t-ALL patient to identify molecular markers 
of the disease. Mutational screening of spliceosome 
machinery (U2AF1 S34 and R35, SF3B1 exons 13–16 
and SRSF2 exon 1), epigenetic enzyme (IDH1 R132, 
IDH2 R140 and R172, DNMT3A R882 and ASXL1 exon 
12), SETBP1 (SKI homologous domain), N-RAS (exons 
2-3) and K-RAS (exons 2-3) was performed using Sanger 
sequencing, whereas TP53 (exons 4-9) mutations were 
studied by standard NGS technology. We identified 8 
mutations (IDH1 R132H, ASXL1 Y591*, ASXL1 S689*, 
ASXL1 R693*, SRSF2 P95H, SF3B1 K700E, SETBP1 
G870R and TP53 Y220C) in seven of thirteen t-MN 
patients (54%), whereas the t-ALL patient was KMT2A-
AFF1-positive. No other recurrent somatic mutations in 
these genes were detected in the remaining 6 patients 
(Table 1).
The apparently low frequency of TP53 mutations 
identified in the present patient cohort (1 in 14 patients) 
may not be considered representative of t-MN in general, 
since it is the result of the particularly restrictive patient 
selection, which included only patients with a previous 
history of hematological malignancies, and available bone 
marrow samples prior to t-MN development.
Validation and quantification of variants
Pyrosequencing analyses, specifically designed to 
quantify the mutations confirmed the data obtained from 
Sanger sequencing in all 8 cases. Mutations identified in 
epigenetic regulators, spliceosome enzymes and SETBP1 
were present at a variant allele frequency (VAF) of 20 to 
42% at the time of t-MN diagnosis (Figure 1), whereas 
the TP53 mutation was detectable at a lower frequency 
(6.75%, Figure 2). Interestingly, UPN9 carried two 
mutations (IDH1 R132H and SRSF2 P95H), at a similar 
VAF (38% and 35%, respectively), suggesting that the 
two mutations were present in the same leukemic clone. 
The mutations were somatically acquired in the myeloid 
compartment, as shown by their presence also in PB-
granulocytes, whereas they were not detectable in the 
CD3+ T-lymphocyte population.
Quantitative evaluation of the KMT2A-AFF1 
transcript in UPN 14 revealed strong positivity for the 
chimeric transcript at the time of t-ALL diagnosis (3500 
copies /104 ABL).
Disease markers and clonal evolution
Using ultra-deep NGS, we then tracked backwards 
by NGS the t-MN clonal markers in BM samples collected 
at the time of the primary hematological malignancy, and 
identified at least two different patterns.
In the first scenario somatic mutations characterizing 
the t-MN clone were not present at primary cancer 
diagnosis and appeared after cytotoxic treatment. In UPN 
3, UPN4, UPN6 and UPN13, the ASXL1 S689*, ASXL1 
R693*, SF3B1 K700E and SETBP1 G870R mutations, 
studied using ultra-deep NGS, were undetectable at the 
time of primary cancer (NHL in UPN3 and UPN4, normal 
karyotype AML in UPN6 and B-ALL with a complex 
karyotype in UPN13) and were detected after 20, 113, 
83 and 32 months from start of primary tumor treatment. 
In UPN4 (Figure 1A), UPN6 and UPN13 the identified 
mutations were detectable for the first time at t-MN 
diagnosis, suggesting a dominant role of these mutations 
in t-MN evolution. In UPN3, the ASXL1 S689* mutation 
was detectable for the first time at NHL follow-up (VAF: 
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Table 1: Patient characteristics
UPN
Age at 
t-MN 
diagnosis 
(yrs)
Gender Primary Malignancy
Treatment 
of primary 
malignancy
BM-
blasts 
(%)
Diagnosis Latency (months) Karyotype
Molecular 
marker
1 73 F NHL ProMACE-
Cytabom + RT
12 t-MDS 100 46,XX [25] ASXL1  
Y591*
2 62 F APL AIDA 2000 
[17]
14 t-MDS 30 46,XX [9] / 42-
45, ring [13]
TP53 Y220C
3 63 M NHL
R-CHOP, 
R-MICMA, 
autoSCT; 
bortezomib/
lenalidomide
4 t-MDS 83 47,XY,+21 [12] ASXL1  
S689*
4 62 F NHL
CHOP, 
MICMA, 
autoSCT, 
fludarabin
8.5 t-MDS 124 46,XX [12] / 
45,XX,-7 [6]
ASXL1  
R693*
5 30 M NHL
CODOX-M/
IVAC,
MICMA, 
autoSCT
10 t-MDS 54 46,XY,-7 [10] absent
6 63 F NK-AML and 
Breast Ca
AML-12 [18], 
Carboplatin, 
taxotere, 
herceptin + RT
10 t-MDS 83
46,XX [24] / 
46,XX,del(5)
(q14q34) [1]
SF3B1
K700E
7 74 F NHL CHOP, R-FC, chlorambucil 19 t-MDS 66 46,XX [25] absent
8 60 F APL AIDA + AutoSCT 6 t-MDS 100
46,XX,-7, +21 
[11] / 45,XX, -7 
[2]
absent
9 81 M NHL Chlorambucil 
+ RT
13 t-MDS 100 Not available IDH1 R132HSRSF2 P95H
10 74 M NHL R-FND, 
R-MICMA
4.5 t-MDS 74
46,XY [19] / 
44,X,-7, del(1)
(p35), del(5)(q13), 
del(11)(q14) [6]
absent
11 37 F HL BEACOPP escalated 18 t-MDS 83
47-49,XX,-7, ring 
[10]/
46,XX [1]
absent
12 50 F HL BEACOPP escalated 43 t-AML 18 46,XX [25] absent
13 43 M ALL GMALL 05/93 
[19]
7 t-MDS 32 45,XY,-7 [6] SETBP1 
G870R
14 40 F APL AIDA 2000 
[17]
80 t-ALL 18
46,XX,
t(4;11)(q21;q23)
[5]
KMT2A/AFF1
Legend: NK: normal karyotype; RT: radiotherapy; ProMACE-CytaBOM: cyclophosphamide, doxorubicin, etoposide, 
bleomycin, vincristine, methotrexate and prednisone; AIDA: ATRA, idarubicine, mitoxantrone; R: Rituximab; CHOP: 
cyclophosphamide, adriblastin, vincristine, prednisone; MICMA: mitoxantrone, carboplatin, cytarabine, methylprednisolone; 
CODOX-M/IVAC: cyclophosphamide, doxorubicin, vincristine, methotrexate, etoposide, ifosfamide and cytarabine; FC: 
fludarabin, cyclophosphamide; FND: fludarabin, mitoxantrone, desametazone; AutoSCT: autologous stem cell transplantation; 
BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone.
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29%, at 20 months), and increased until the time of t-MN 
diagnosis (VAF: 35%, 86 months). Of note, the ASXL1 
S689* was first detected following peripheral blood stem 
cell transplantation (PB-SCT, Figure 1B). In UPN 6, who 
had two primary malignancies (AML and BC), the SF3B1 
mutation may have been induced by the chemotherapy 
used to treat AML or by the combined radio-chemotherapy 
approach used to treat BC. In this case we have no data 
to precisely unravel the genomic effects of the different 
treatments.
Similarly, the KMT2A-AFF1 fusion identified in 
UPN14 at t-ALL diagnosis, as expected, was undetectable 
in the primary APL diagnostic sample, and was detected 
at low levels by Q-RT-PCR 13 months after achievement 
of complete remission of APL, treated according to the 
AIDA protocol (Figure 1C, 17). Notably, a constant 
increase in the transcript copy number was evident from 
first identification (58 copies/104 ABL) to t-ALL onset 
(3522 copies/104 ABL). The patient did not achieve 
molecular response after induction treatment for ALL 
using clofarabine and cyclophosphamide (4390 copies/104 
ABL), whereas re-induction treatment according to 
the LAL0904 protocol (3 courses of Vincristine and 
Daunorubicin, 20) resulted in complete hematological 
and molecular remission. UPN14 subsequently underwent 
allogeneic stem cell transplantation (ASCT) from an HLA-
identical related donor with T-cell depletion and is to-date 
in complete hematological and molecular remission 54+ 
months after ASCT.
Figure 1: Genetic changes present in t-MN were not detectable at primary cancer diagnosis. A. In UPN4, the ASXL1 
R693* mutation detected in the t-MN sample was undetectable at the time of NHL diagnosis (113 months prior to t-MN onset). B. 
In UPN3, the ASXL1 S689* mutation was undetectable at the time of primary cancer diagnosis (NHL) but was detectable for the first 
time during NHL follow-up (at 20 months) and increased until the time of t-MN diagnosis (at 86 months). Of note, the mutation was 
first detected after high-dose therapy and PB-SCT. C. Similarly, the KMT2A-AFF1 fusion identified in UPN 14 at t-ALL diagnosis was, 
as expected, undetectable in the primary APL diagnostic sample, and was detected at low levels by Q-RT-PCR thirteen months after 
achievement of complete molecular remission of APL, using the AIDA 2000 protocol [17]. Notably, a constant increase in the transcript 
copy number was evident from first identification (58 copies/104 ABL) to t-ALL onset (3522 copies/104 ABL). The fusion transcript became 
undetectable only after re-induction treatment according to the LAL0904 protocol [27] and resulted to date undetectable (54+ months) after 
ASCT. The variant allele frequency (VAF) is indicated. Legend. NHL DG: non-Hodgkin lymphoma diagnosis; t-MN DG: therapy-related 
myeloid neoplasm diagnosis; APL DG: acute promyelocitic leukemia diagnosis; CR: complete remission; t-ALL DG: therapy-related acute 
lymphoblastic leukemia diagnosis; Allo-SCT: allogeneic stem cell transplantation; CHOP: cyclophosphamide, adriblastin, vincristine, 
prednisone; MICMA: mitoxantrone, carboplatin, cytarabine, methylprednisolone; PB-SCT: peripheral blood stem cell transplantation; 
RTX: radiotherapy; CTX: cyclophosphamide; HD-CTX: high-dose cyclophosphamide; R-MICMA: mitoxantrone, carboplatin, cytosine 
arabinoside, and methylprednisolone; R-Vel-dex: lenalidomide, bortezomib, dexametasone; AIDA: ATRA, idarubicine.
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A different pattern was observed in UPN1, UPN2 
and UPN9, where mutations were detectable in the primary 
BM sample, prior to any cytotoxic treatment. In particular, 
the specific TP53 Y220C mutation was identified in UPN2 
in all available BM-MNC specimens, from APL diagnosis 
through complete remission phases, and finally in t-MN. 
However, the TP53 Y220C mutation was undetectable in 
mesenchymal stromal cells (MSC) cultured from the BM 
at t-MN diagnosis, indicating that the mutation had been 
acquired by hematopoietic cells only. A high-throughput 
NGS analysis revealed a constant increase in the mutated 
allele frequency from APL to t-MN onset (Figure 2A).
Similarly, the ASXL1 Y591* mutation was identified 
in UPN1 in all the available BM-MNC specimens, from 
NHL diagnosis to t-MN. Notably, ASXL1 Y591* mutation 
was detected at very low level in the NHL BM-specimen 
(0.3%), significantly increased at 31 month follow-up 
(7%) and reached the highest VAF at t-MN diagnosis 
(42%, Figure 2B).
UPN9 was characterized by a particular pattern, 
with the IDH1 R132H mutation present at NHL 
diagnosis, whereas the SRSF2 P95H mutation appeared 
at t-MN onset (Figure 2C). In particular, the IDH1 R132H 
mutation, originally present at a high allele frequency 
Figure 2: Somatic mutations were present prior to any cytotoxic treatment. A. A TP53 Y220C mutation was identified in 
UPN2 in all the available BM-MNC specimens, from APL diagnosis to complete remission, and expanded in the t-MN clone. B. Similarly, 
in UPN1 the ASXL1 Y591* mutation was identified in all the available BM-MNC specimens, from NHL diagnosis to t-MN. Notably, 
this mutation was detected at very low levels in the BM NHL specimen (0.3%), significantly increased at 31 months follow-up (7%) and 
reached the highest VAF at t-MN diagnosis (42%). C. In UPN9, the IDH1 R132H mutation was originally present at a high allele frequency 
at NHL diagnosis, 9 years before t-MN onset, when the patient was 72 years old, indicating that this mutation could have occurred as a 
pre-leukemic event. The SRSF2 P95H mutation was acquired later, at the time of t-MN diagnosis. Legend: APL DG: acute promyelocitic 
leukemia diagnosis; CR: complete remission; NHL DG: non-Hodgkin lymphoma diagnosis; t-MN DG: therapy-related myeloid neoplasm 
diagnosis; AIDA: ATRA, idarubicine; RT: radiotherapy; ProMACE-CytaBOM: cyclophosphamide, doxorubicin, etoposide, bleomycin, 
vincristine, methotrexate and prednisone.
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(35%) 9 years before t-MN onset, when the patient was 72 
years old, indicates that this mutation could have occurred 
as a pre-leukemic event. The later acquisition of a SRSF2 
P95H mutation suggests its role in t-MN pathogenesis in a 
susceptible individual.
Altogether, these data suggest that different patterns 
of therapy-related leukemogenesis may occur in different 
patients.
DISCUSSION
Changes in cytotoxic treatment for different 
malignancies have modified the incidence of t-MN [16]. 
Since only a small proportion of cancer patients develop 
a t-MN, individual susceptibility to this disease is one 
of the topics of major interest. In the past years, several 
authors have suggested that germ-line variants may play 
a major role in t-MN predisposition. Candidates are 
polymorphisms of genes implicated in detoxification, 
DNA repair and apoptosis pathways [21–23], or single 
nucleotide variants (SNV) affecting cancer predisposition 
genes, such as Fanconi anemia genes [7, 24]. Although 
next generation sequencing approaches have allowed the 
acquisition of detailed information, a direct and univocal 
mechanism to explain t-MN susceptibility has not been 
identified yet.
Recently, somatic mutations in critical genes, 
including DNMT3A, ASXL1 and TP53 have been identified 
in the PB of healthy elderly individuals, indicating that 
mutated clones may spontaneously emerge as a result 
of the aging process [14–15]. In this scenario, therapy-
related leukemia would not be a direct consequence of 
cytotoxic treatment, but the result of clonal selection 
due to cytotoxic treatment administered to predisposed 
individuals.
In the present investigation, we studied the time-
course of the appearance of somatic mutations in genes 
known to be involved in hematological malignancies 
during therapy-related leukemogenesis.
Our results highlight at least two different models. 
In a first model, mutations were acquired probably as 
a consequence of cytotoxic treatment, where ASXL1 
S689* (UPN3), ASXL1 R693* (UPN4), SF3B1 K700E 
(UPN6) and SETBP1 G870R (UPN13) mutations were 
only detectable at the time of t-MN diagnosis, and were 
apparently absent in the BM-MNC harvested at time of 
primary tumor diagnosis and during follow-up. Although 
we cannot exclude the presence of minor clones (VAF 
<0.1%) in UPN3, UPN4, UPN6 and UPN13, our results 
suggest that the ASXL1 S689*, ASXL1 R693*, SF3B1 
K700E and SETBP1 G870R mutations may be directly 
induced by chemo- and/or radiotherapy. The acquisition 
of these mutations at high VAF may play a pivotal role in 
the development of t-MN.
Similarly, in UPN14, the KMT2A-AFF1 transcript 
was not amplified at APL diagnosis and was detected 
for the first time 14 months after APL treatment start, 
during maintenance treatment that was being given 
according to the AIDA 2000 protocol [17]. The KMT2A/
AFF1 copy number progressively increased later on, until 
t-ALL diagnosis. The standard AIDA protocol includes 
consolidation with mitoxantrone, a topoisomerase-
II inhibitor, known to be involved in DNA-damage 
specifically targeting the KMT2A gene [25]. t-MN 
following Topo-II inhibitors are also characterized by short 
latency, as in this case, where the KMT2A/AFF1-positive 
clone became detectable 13 months after treatment start. 
The high curability of APL highlights the importance of 
avoiding genotoxic and mutagenic drugs in this disease, 
where chemotherapy-free regimens including arsenic-
trioxide have shown high curative potential at least in non-
high risk patients [26].
In the second scenario, somatic mutations were 
present in the marrow harvested at the time of primary 
cancer diagnosis. This is exemplified by UPN2, who 
carried a TP53 Y220C mutation at a frequency of 0.1% 
at primary APL diagnosis, progressively increasing in 
serial follow-up samples, and until t-MN onset. A low, 
but significant number (6%), of TP53 mutated cells may 
suffice to guide t-MN development. This same pattern 
has been previously identified by Wong et al. in four of 
seven t-MN patients, suggesting that cytotoxic therapy 
does not directly induce TP53 mutations, but selects for 
hematopoietic progenitor cells carrying spontaneous TP53 
mutations, which are more resistant to chemotherapy 
than TP53 wild-type cells [13]. The presence of TP53 
mutations could contribute to the typical genetic instability 
of t-MN, associated with complex karyotypes and poor 
response to chemotherapy.
The same scenario identified in UPN2 could be 
hypothesized in UPN1, where the ASXL1 Y591* mutation 
was detected at low frequency (0.3%) at primary NHL 
diagnosis and progressively increased in serial follow-up 
samples, reaching a very high VAF at the time of t-MN 
diagnosis (42%).
In UPN9, we found two mutations in the t-MN 
sample (IDH1 R132H and SRSF2 P95H), but only the 
IDH1 R132H was present at the time of NHL diagnosis, 
probably acting as predisposing factor for the acquisition 
of the second mutation. The similar VAF (35-38%) of the 
two mutations suggests their presence in the same cell 
clone, although we cannot exclude that two independent 
clones were simultaneously present. According to the 
literature, IDH1 mutations are rare or absent in NHL, 
therefore it seems unlikely that these were present in the 
NHL clone in our case [27]. The high VAF of the IDH1 
mutation in the initial BM sample (35%) which remained 
virtually unchanged at t-MN diagnosis (38%) may 
indicate independence of this clone from the pressure of 
cytotoxic therapy with chlorambucil. Since this drug has 
only rarely been associated with t-MN, it remains unclear 
whether this was a true therapy-related MDS or a second 
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neoplasm occurring in a susceptible patient [28]. In this 
line, Lindsley et al, have recently shown that mutations 
of splicing and epigenetic enzymes may distinguish AML 
subtypes which are “secondary” to MDS, from truly 
therapy-related forms [9].
In conclusion, our data show that secondary 
leukemogenesis is a heterogeneous process at least 
in cases with a previous hematological malignancy. 
Somatic mutations in critical genes may precede and 
favor leukemic development or may be induced by the 
cytotoxic treatment. Additional studies in extended patient 
cohorts with a longitudinal follow-up, together with 
further advances in NGS technology and digital PCR, 
are needed to define the contribution of minor clones to 
therapy-related leukemogenesis. This will also help to 
identify patients at major risk at the time of primary cancer 
diagnosis, where more leukemogenic treatments could be 
avoided and a more stringent follow-up monitoring should 
be recommended.
MATERIALS AND METHODS
Study population
Our study population included 14 patients (13 
t-MN and one t-ALL), diagnosed at the Department of 
Hematology of the Università Cattolica del Sacro Cuore 
and at Tor Vergata University between November 2003 
and March 2014. Cases were selected based on availability 
of DNA from secondary leukemia diagnosis and at least 
one preceding phase (e.g. marrows collected during 
follow-up of the primary tumor). There were 5 males and 
9 females, with a median age at t-MN diagnosis of 58 
years (range 30–81). According to the proportion of blasts, 
there were 12 MDS, 1 AML and 1 B-lineage ALL. The 
primary malignancies were all hematological and included 
non-Hodgkin lymphoma (NHL) in 7 patients, Hodgkin 
lymphoma (HL) in 2 patients, acute promyelocytic 
leukemia (APL) in 3 patients, normal-karyotype AML 
followed by breast cancer (BC) in 1 patient and B-ALL 
in 1 patient. Detailed patient characteristics are reported 
in Table 1. All peripheral blood (PB) and BM samples 
were obtained after informed consent. The study has been 
approved by the Institutional Ethical Committees of the 
Università Cattolica del Sacro Cuore and Tor Vergata 
University.
Mutational analysis
Mononuclear cells (MNCs) were separated from 
patients’ BM at the time of the primary cancer diagnosis, 
during its follow-up and at t-MN diagnosis by Ficoll 
gradient centrifugation using Lympholyte-H (Cedarlane, 
Ontario, Canada). As previously reported [29], BM-
mesenchymal stem cells (MSC) were expanded in UPN2 
using Mesencult medium (Stem Cell Technologies, Voden 
Medical Instruments, Milan, Italy) in plastic-adherent 
cultures up to the second passage. Granulocyte, CD3+ 
and CD3- cells were isolated at t-MN diagnosis from the 
peripheral blood of UPN9 by Ficoll gradient centrifugation 
followed by MACS cell separation (Miltenyi biotec, Italy).
Genomic DNA was extracted using the QIAamp 
DNA Mini Kit (Qiagen Srl., Milan, Italy), following 
the manufacturer’s instructions, whereas total RNA 
was extracted using standard procedures and reverse-
transcribed using random hexamers as primers [30]. 
The following mutations were studied at the time of 
t-MN diagnosis by Sanger sequencing of genomic DNA: 
IDH1 R132, IDH2 R140 and R172, DNMT3A R882, 
ASXL1 exon 12, U2AF1 S34 and R35, SF3B1 exons 
13–16, SRSF2 exon 1, SETBP1 SKI homologous domain, 
NRAS exons 2-3 and KRAS exons 2-3 as previously 
described (ABI PRISM 3100; Applied Biosystems/Life 
Technologies, Milan, Italy, 10-11, 31). All mutations 
were confirmed in independent experiments and 
quantified by pyrosequencing using specifically designed 
oligonucleotides targeting the mutated region (shown in 
Supplementary Table 1). Reagents (PyroMark Gold Q96, 
QiagenSrl, Milan, Italy), instrumentation and analysis 
software used for pyrosequencing analysis were as 
recommended by the manufacturers (PyroMark Q96 ID, 
DiatechPharmacogenetics, Jesi, Italy, PyroMark Assay 
Design and PyroMark Q24 version 2.0.6).
TP53 mutations were studied at the time of t-MN 
diagnosis by standard NGS, since mutations of this gene 
have been detected at low VAF by several authors at t-MN 
diagnosis. Briefly, genomic DNA was amplified using Fast 
Start High Fidelity Polymerase (Roche, Monza, Italy) and 
fusion primers (Roche, Monza, Italy) containing M13 
adapter sequences and the sequence-specific primers 
(Supplementary Table 1) spanning TP53 exons 4-9 
(RefSeq NM_000546.5, representing the longer transcript 
encoding the longest protein isoform). Amplicon library 
A and B sequencing adapters and multiplex identifier 
(MID) tags were then added to both tails of amplicons 
by a second amplification step. PCR products were 
visualized on agarose gel, purified using AMPure XP 
DNA-binding paramagnetic beads (Agencourt Bioscience 
Corp., Beckman Coulter S.p.A, Milan, Italy), and 
quantified using the picogreen dye (Life Technologies, 
Carlsbad, California) and the Victor X2 fluorometer 
(Perkin Elmer, Waltham, Massachusetts). Samples were 
then pooled at equimolar ratios to prepare for Roche/454 
pyrosequencing. The obtained amplicon library was 
added to the emulsion PCR at a ratio of 0.8 molecules per 
bead and subjected to deep sequencing on the Genome 
Sequencer Junior instrument (Roche-454 Life Sciences, 
Branford, Connecticut). The obtained sequencing reads 
were mapped to the TP53 human reference sequence 
(RefSeq NC_000017.11) and analyzed by the Amplicon 
Variant Analyzer (AVA) software version 3.0 (Roche-454 
Life Sciences) to establish the mutant allele frequency.
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The mutations identified in the t-MN sample were 
then studied in marrow samples collected at the time of 
primary diagnosis and/or during follow-up using high-
throughput NGS (Sistemas Genòmicos S.L., Valencia, 
Spain). Briefly, genomic DNA was amplified by PCR 
using specific homemade designed primers linked to 
specific flags (Supplementary Table 1). Amplicons 
resequencing was performed using the Illumina MiSeq 
sequencing platform and NexteraXT PCR enrichment 
(Illumina, San Diego, CA, USA). Paired-end’ reads of 250 
nt were generated. Then, targeted regions were enriched 
using the Nextera XT DNA kit (Illumina, San Diego, CA, 
USA). For the amplicon data analysis, three different 
plots were generated for each sample’s read group: per 
base sequence quality, per base sequence content and per 
sequence quality scores. To remove the background noise 
and to assure that only very confident high quality reads 
were used to perform read alignment, Nextera adapters 
were removed using FASTQ-MCF software. Reads were 
then collapsed using UPARSE [32] to merge the paired-
end reads into a single better quality read (no mismatches 
allowed). Then PRINSEQ [33] was used to remove low 
quality reads in both 5’ and 3’ ends. Collapsed reads were 
aligned separately against the human reference genome 
version GRCh38. Read alignment was performed using 
BWA and ‘in-house’ scripts (Sistemas Genòmicos S.L., 
Valencia, Spain). From the BAM formatted file obtained 
after reads mapping, low quality reads were removed. In 
addition, the overall sample coverage and the efficiency of 
the combination of the selected strategy (PCR enrichment 
system plus NGS platform) were evaluated. Filtering 
processes were performed using Picard-tools (http://
picard.sourceforge.net/) and SAM tools [34]. Coverage 
metrics and the evaluation of the target enrichment 
system were performed using custom scripts (Sistemas 
Genómicos S.L., Valencia, Spain). For each of the 
corresponding specific amplicon regions average coverage 
was above 120000x for all the samples in the experiment 
(detailed read depth in Supplementary Table 2). To 
avoid bias, for the quantification of studied mutations all 
collapsed mapped reads were used to establish the count 
and frequencies in % (alternative allele count/total depth 
x100).
Detection and quantification of the KMT2A-
AFF1, transcript
Qualitative screening of the t(4;11)(q21;q23) 
translocation resulting into the KMT2A-AFF1 fusion 
transcript was performed in UPN14 at the time of 
diagnosis of a therapy-related B-ALL, according to van 
Dongen, et al. [35]. The quantitative analysis for KMT2A-
AFF1 was performed according to Gabert J, et al. [36] at 
the time of the primary acute promyelocytic leukemia and 
at various time points during its follow-up.
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